The relationship between serum CXCL16, Trx80, and cognitive function/prognosis in Alzheimer′s disease patients
10.3760/cma.j.cn431274-20230522-00742
- VernacularTitle:阿尔茨海默病患者血清CXCL16、Trx80水平与认知功能和预后的关系
- Author:
Longfang LIU
1
;
Li YUE
;
Jiayao SUN
Author Information
1. 张家口市第一医院神经内二科，张家口 075000
- Keywords:
Alzheimer disease;
Chemokine CXCL16;
Thioredoxin 80;
Cognition
- From:
Journal of Chinese Physician
2024;26(3):387-391
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relationship between serum C-X-C motif chemokine ligand 16 (CXCL16) and thioredoxin 80 (Trx80) in patients with Alzheimer′s disease (AD) and cognitive function and prognosis.Methods:A total of 189 AD patients admitted to the Zhangjiakou First Hospital from January 2020 to August 2021 were selected as the AD group, and 110 healthy volunteers who underwent physical examinations in our hospital during the same period were selected as the control group. The serum levels of CXCL16 and Trx80 were detected using enzyme-linked immunosorbent assay (ELISA), and cognitive function was evaluated using the Mini Mental State Examination (MMSE) score. The Spearman correlation method was used to analyze the correlation between serum CXCL16, Trx80 levels and MMSE scores in AD patients. 189 AD patients were divided into poor prognosis group and good prognosis group based on their prognosis. Univariate and multivariate logistic regression methods were used to analyze the influencing factors of poor prognosis in AD patients. Receiver operating characteristic (ROC) curves were used to analyze the predictive value of serum CXCL16 and Trx80 levels for poor prognosis in AD patients.Results:Compared with the control group, the AD group had higher serum levels of CXCL16 and Trx80, and lower MMSE scores (all P<0.05). Spearman correlation analysis showed that the serum levels of CXCL16 and Trx80 in AD patients were negatively correlated with MMSE scores (all P<0.05). After a one-year follow-up, the poor prognosis rate of 189 AD patients was 32.80%(62/189). Univariate analysis showed that age, disease duration, β-amyloid protein (Aβ) 1-40, Aβ 1-42, MMSE score, CXCL16, and Trx80 are associated with poor prognosis in AD patients (all P<0.05). Multivariate logistic regression analysis showed that age, prolonged disease course, and elevated levels of CXCL16 and Trx80 were risk factors for poor prognosis in AD patients (all P<0.05), while an increase in MMSE score was a protective factor ( P<0.05). ROC curve analysis showed that the area under the curve (AUC) of MMSE score, CXCL16, Trx80, CXCL16+ Trx80 combination, and MMSE score+ CXCL16+ Trx80 combination predicting poor prognosis in AD patients were 0.750, 0.763, 0.771, 0.851, and 0.896, respectively. The AUC of the three combination predicting poor prognosis in AD patients was the highest. Conclusions:Elevated serum levels of CXCL16 and Trx80 in AD patients are associated with decreased cognitive function and poor prognosis, and may become auxiliary predictive indicators for poor prognosis in AD patients.
